Search

Wave energy is one of the renewable energy sources with the highest potential. Several pilot plants have been built based on the principle of the Oscillating Water Column (OWC). Among the different solutions that have been suggested, the Wells turbine has gained particular attention due to its simplicity and reliability. The majority of available studies concentrate on the steady operation of the Wells turbine, while only few analyze its performance under an unsteady and bi-directional air flow, as determined by the presence of the OWC system. In this work, experimental and numerical performance of a high-solidity Wells turbine with NACA0015 profiles have been compared, at different non-dimensional piston frequencies. The numerical simulations have been conducted using commercial CFD software and focus on unsteady predictions, with particular attention to the behavior of the flow upstream and downstream of the rotor, flow hysteresis between acceleration and deceleration phases and differences between intake and exhaust strokes due to the non-symmetrical configuration of the machine. [ABSTRACT FROM AUTHOR]

Background: Hemofiltrate reinfusion (HFR) is a form of hemodiafiltration (HDF) in which replacement fluid is constituted by ultrafiltrate from the patient 'regenerated' through a cartridge containing hydrophobic styrene resin. Bicarbonate-based dialysis solutions (DS) used in routine hemodialysis and HDF contain small quantities of acetate (3-5 mM) as a stabilizing agent, one of the major causes of intradialytic hypotension. Acetate-free (AF) DS have recently been made available, substituting acetate with hydrochloric acid. The impact of AF DS during HFR on Hb levels and erythropoietic-stimulating agent (ESA) requirement in chronic dialysis patients was assessed. Patients and Methods: After obtaining informed consent, 30 uremic patients treated by standard bicarbonate dialysis (BHD, DS with acetate) were randomized to treatment in 3-month cycles: first AF HFR, followed by HFR with acetate, and again AF HFR. At the beginning and end of each period, Hb and ESA requirements were evaluated. Results: A significant increase in the Hb level was observed throughout all periods of HFR versus BHD (from 11.1 to 11.86 g/dl; p = 0.04), with a significant decrease of ESA requirements from 29,500 to 25,033 IU/month (p = 0.04). Conclusion: Regardless of the presence or absence of acetate in DS, HFR per se allows a significant lowering of ESA dosage versus BHD, while at the same time increasing Hb levels. Taking for granted the clinical impact produced, HFR seems to provide a relevant decrease in end-stage renal disease patient costs. Copyright © 2011 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]